Contract manufacturer CordenPharma, recently tapped in a German push to earmark mRNA vaccine capacity, is getting a new owner.
Biogen’s yearlong struggle with the controversial FDA approval and launch of Aduhelm has culminated in a deep overhaul reaching all the way to the CEO.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.